NCT05907304 2026-02-27
SEACRAFT-1
Erasca, Inc.
Phase 1 Active not recruiting
Clinical Trials
34 trialsNCT03333343 2026-01-16
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
Novartis
Phase 1 Active not recruiting
NCT04111458 2026-01-12
A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT04294160 2025-12-24
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
Novartis
Phase 1 Terminated
NCT05668585 2025-11-21
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors
C4 Therapeutics, Inc.
Phase 1 Completed
NCT04185883 2025-10-22
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Amgen
Phase 1 Active not recruiting
NCT02974725 2025-04-13
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
Novartis
Phase 1 Terminated
NCT04965220 2023-08-09
HLX208 (BRAF V600E Inhibitor) in Combination With Trametinib in Patients With Advanced Solid Tumors
Shanghai Henlius Biotech
Phase 1 Unknown
NCT02900664 2022-03-29
A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)
Novartis
Phase 1 Completed
NCT02705963 2022-02-09
A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors
Novartis
Phase 1 Completed
NCT02110355 2021-03-26
A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
Kartos Therapeutics, Inc.
Phase 1 Completed
NCT02703571 2020-12-21
Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors
Novartis
Phase 1 Terminated
NCT01155453 2020-12-09
A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients
Novartis
Phase 1 Completed
NCT01938443 2019-07-12
A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT02027961 2019-05-17
Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone
MedImmune LLC
Phase 1 Completed
NCT01231594 2019-03-22
A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors
Novartis
Phase 1 Completed
NCT02258607 2019-02-01
Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase
Sierra Oncology LLC - a GSK company
Phase 1 Terminated
NCT02447939 2018-09-14
Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma
GlaxoSmithKline
Phase 1 Withdrawn
NCT02939846 2018-09-14
Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours
GlaxoSmithKline
Phase 1 Withdrawn
NCT02065063 2018-06-01
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT01767454 2017-11-14
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
GlaxoSmithKline
Phase 1 Completed
NCT00687622 2017-11-13
Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma
GlaxoSmithKline
Phase 1 Completed
NCT01138085 2017-11-13
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
GlaxoSmithKline
Phase 1 Completed
NCT01192165 2017-11-13
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
GlaxoSmithKline
Phase 1 Completed
NCT01371487 2017-11-13
GSK1120212 Food-effect Study
GlaxoSmithKline
Phase 1 Completed
NCT01387204 2017-11-13
Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212
GlaxoSmithKline
Phase 1 Completed
NCT01416337 2017-11-13
Absolute Bioavialability of GSK1120212
GlaxoSmithKline
Phase 1 Completed
NCT01428427 2017-11-13
Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00955773 2017-11-09
Cancer
GlaxoSmithKline
Phase 1 Completed
NCT02538627 2017-09-05
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
Merrimack Pharmaceuticals
Phase 1 Terminated
NCT01248858 2017-05-09
Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.
GlaxoSmithKline
Phase 1 Terminated
NCT01287546 2017-02-15
A Study of LY2875358 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02292732 2016-01-26
A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors
GlaxoSmithKline
Phase 1 Withdrawn
NCT01938456 2014-07-28
Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer
GlaxoSmithKline
Phase 1 Withdrawn